Literature DB >> 18975314

Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features.

Elizabeth Stringer1, Davinder Singh-Grewal, Brian M Feldman.   

Abstract

OBJECTIVE: Juvenile dermatomyositis (DM) is a rare chronic inflammatory disease of childhood. The clinical course of juvenile DM appears to be variable, and little is known about predictors of the disease course. The aims of this study were to describe the clinical course of juvenile DM and to determine whether early clinical and laboratory features can be used to predict the time to remission and/or the disease course.
METHODS: Clinical and laboratory data from a cohort of 84 patients with juvenile DM were prospectively entered into a database (1990-2005). Remission was defined as a clinical state of no active skin rash, weakness, or elevated muscle enzyme levels for 6 months off medication. The disease course was defined as monophasic, polyphasic, or chronic. Data were reviewed at the time of diagnosis and at 3 months and 6 months after the diagnosis to determine predictors of the time to remission and/or the disease course.
RESULTS: The median time to remission was 4.67 years. Sixty percent of patients had a chronic course, 37% a monophasic course, and 3% a polyphasic course. The presence of rash (most strongly indicated by Gottron's papules) at 3 months was the earliest predictor of a longer time to remission (relative risk [RR] 0.55 [95% confidence interval (95% CI) 0.37-0.81], P = 0.002). At 6 months, the presence of nailfold abnormalities and rash also predicted a longer time to remission (RR 0.35 [95% CI 0.14-0.74], P = 0.003). We were unable to determine a prediction model of disease course.
CONCLUSION: The majority of patients in our cohort had a chronic disease course. The persistence of Gottron's papules and nailfold abnormalities early in the disease course was associated with a longer time to remission.

Entities:  

Mesh:

Year:  2008        PMID: 18975314     DOI: 10.1002/art.23960

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  28 in total

1.  Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?

Authors:  Lisa G Rider; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2010-09

2.  Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Authors:  G Esther A Habers; Adam M Huber; Gulnara Mamyrova; Ira N Targoff; Terrance P O'Hanlon; Sharon Adams; Janardan P Pandey; Chantal Boonacker; Marco van Brussel; Frederick W Miller; Annet van Royen-Kerkhof; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

Review 3.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 4.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 5.  Juvenile dermatomyositis.

Authors:  Michelle Batthish; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 6.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

7.  Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.

Authors:  Takayuki Kishi; William Warren-Hicks; Nastaran Bayat; Ira N Targoff; Adam M Huber; Michael M Ward; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

8.  Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis.

Authors:  Rochella A Ostrowski; Christine L Sullivan; Roopa Seshadri; Gabrielle A Morgan; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2010-05

9.  A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies.

Authors:  Neil Martin; Petra Krol; Sally Smith; Kevin Murray; Clarissa A Pilkington; Joyce E Davidson; Lucy R Wedderburn
Journal:  Rheumatology (Oxford)       Date:  2010-09-07       Impact factor: 7.580

Review 10.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.